Ancora.ai
Ancora.ai is a digital platform founded in 2017 that connects cancer patients to clinical trials, improving the referral process and patient experience. With a team of nine, the company specializes in artificial intelligence, personalized medicine, and health equity within the healthcare industry.
Company Overview
Ancora.ai is a digital platform designed to enhance the experience of cancer patients by pre-screening and referring them to clinical trials. Founded in 2017, the company operates within the Hospitals and Health Care industry. With a team size of 9, Ancora.ai is classified as a very small business. The company emphasizes a patient-first approach, aiming to streamline the referral process for clinical trials.
Technology and Specialties
Ancora.ai utilizes advanced technologies such as neural networks, deep learning, and natural language processing (NLP) to facilitate clinical trial referrals. The platform focuses on personalized and precision medicine, ensuring that cancer patients receive tailored treatment options. Additionally, the company is committed to health equity and patient centricity, striving to improve access to clinical trials for diverse patient populations.
Locations
Ancora.ai is headquartered in Zurich, Switzerland, with additional locations in Berlin, Germany, and Zadar, Croatia. These locations support the company's mission to connect cancer patients with clinical trials and enhance their overall healthcare experience.
Partnerships and Collaborations
Ancora.ai actively seeks strong partnerships to foster innovation and improve accessibility to clinical trials. By collaborating with various stakeholders in the healthcare ecosystem, the company aims to reduce the burden of clinical trial referrals and enhance the patient experience.
Industry Sector
Ancora.ai operates within the Hospitals and Health Care sector, specifically focusing on oncology and cancer treatment. The company's digital platform addresses the challenges faced by cancer patients in accessing clinical trials, thereby contributing to advancements in cancer care and research.